From the WUSTL Newsroom…
Randall Bateman, MD, has been named the Charles F. and Joanne Knight Distinguished Professor in Neurology at Washington University School of Medicine in St. Louis.
Chancellor Mark S. Wrighton and Larry J. Shapiro, MD, executive vice chancellor for medical affairs and dean of the School of Medicine, announced the appointment.
“Thanks to Randy’s exceptional research, we have taken important steps forward in the long battle to understand and conquer Alzheimer’s disease,” Wrighton says. “We’re grateful that the generosity of Chuck and Joanne Knight will allow us to further support his research with a new endowed professorship.”
“In both the laboratory and the clinic, Randy has had a remarkable impact on Alzheimer’s disease research and treatment,” Shapiro says. “He’s now making preparations to lead a first-of-its-kind clinical trial to see if we can stop Alzheimer’s disease before symptoms start to appear.”
Bateman was officially installed in his new position at a ceremony May 21. Earlier that month, he received the MetLife Foundation’s Promising Young Investigator Award.
Bateman treats patients with dementia at the Memory Diagnostics Center at Barnes-Jewish Hospital. He has been a faculty member at the School of Medicine since 2006.
“I am honored to be appointed as the first Charles F. and Joanne Knight Distinguished Professor,” Bateman says. “Chuck and Joanne Knight have been exceptional supporters of Alzheimer’s research for many years now, and that support has catalyzed Alzheimer’s research and helped launch the field into an exciting new era.”
Bateman developed a technique that made it possible to answer a critical question about Alzheimer’s disease: Do Alzheimer’s patients get brain plaques because they’re making more amyloid beta, the main ingredient of the plaques, or because their ability to clear amyloid beta from the brain is declining? Bateman’s innovation, known as stable isotope-labeling kinetics (SILK), made it possible to answer this question by tagging a component of the amyloid beta protein, allowing scientists to track amyloid beta production and clearance rates.
For more from Michael C. Purdy of the WUSTL Newsroom, click here.